- Home
- ADAP vs NVNO Comparison
ADAP vs NVNO Comparison
Compare ADAP & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- NVNO
- Stock Information
- Founded
- ADAP 2008
- NVNO 1987
- Country
- ADAP United Kingdom
- NVNO United States
- Employees
- ADAP N/A
- NVNO N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- ADAP Health Care
- NVNO Health Care
- Exchange
- ADAP Nasdaq
- NVNO Nasdaq
- Market Cap
- ADAP 71.6M
- NVNO 61.9M
- IPO Year
- ADAP 2015
- NVNO N/A
- Fundamental
- Price
- ADAP $0.21
- NVNO $2.74
- Analyst Decision
- ADAP Strong Buy
- NVNO
- Analyst Count
- ADAP 5
- NVNO 0
- Target Price
- ADAP $1.93
- NVNO N/A
- AVG Volume (30 Days)
- ADAP 2.4M
- NVNO 75.2K
- Earning Date
- ADAP 03-20-2025
- NVNO 05-07-2025
- Dividend Yield
- ADAP N/A
- NVNO N/A
- EPS Growth
- ADAP N/A
- NVNO N/A
- EPS
- ADAP N/A
- NVNO N/A
- Revenue
- ADAP $178,032,000.00
- NVNO N/A
- Revenue This Year
- ADAP N/A
- NVNO N/A
- Revenue Next Year
- ADAP $56.87
- NVNO $409.09
- P/E Ratio
- ADAP N/A
- NVNO N/A
- Revenue Growth
- ADAP 195.34
- NVNO N/A
- 52 Week Low
- ADAP $0.20
- NVNO $2.45
- 52 Week High
- ADAP $1.55
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- ADAP 14.09
- NVNO 40.78
- Support Level
- ADAP $0.26
- NVNO $2.79
- Resistance Level
- ADAP $0.47
- NVNO $2.97
- Average True Range (ATR)
- ADAP 0.04
- NVNO 0.15
- MACD
- ADAP -0.02
- NVNO 0.00
- Stochastic Oscillator
- ADAP 1.23
- NVNO 36.11
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).